NCT06034002 2026-03-16
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
Clinical Trials
11 trialsNCT06150157 2026-03-16
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05936359 2026-02-10
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT03571321 2026-01-09
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
University of Chicago
Phase 1 Recruiting
NCT05088356 2025-12-19
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1 Recruiting
NCT05010005 2025-12-03
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06291987 2025-11-05
MPN
University of Chicago
Phase 1 Recruiting
NCT03017820 2025-10-08
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT03874052 2025-08-29
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT06225310 2025-01-16
KPT-IST-391
Oncotherapeutics
Phase 1 Recruiting
NCT03110822 2023-11-01
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Oncotherapeutics
Phase 1 Recruiting